用talquetamab准GPRC5D:对于复发性/阻断性多发性髓瘤的双特异性抗体疗法的新前沿
Jacob Shaver1, Daniel Horton1, Zachery Halford1
1College of Pharmacy, Union University, Jackson, TN, USA.
The Annals of pharmacotherapy
|August 28, 2024
概括
Talquetamab-tgvs为复发性或耐火性多发性骨髓瘤 (MM) 提供了一种新的治疗方法,其反应率很高. 需要进一步的研究来确定其在MM治疗中的长期作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性或耐火性多发性骨髓瘤 (R/R MM) 呈现出显著的未满足需求.
- 新型治疗策略对于改善R/RMM患者的治疗结果至关重要.
研究的目的:
- 评估talquetamab-tgvs对R/R MM的药理学,临床疗效,安全性,剂量,管理和临床影响.
- 评估talquetamab-tgvs作为一种新的双特异抗体治疗选择.
主要方法:
- 在PubMed和ClinicalTrials.gov (2000-2024) 的文献搜索中使用关键词:talquetamab,Talvey,JNJ-64407564和多发性髓瘤.
- 临床试验,指南和处方信息的系统审查和分析.
主要成果:
- 在MonumenTAL-1试验中,Talquetamab-tgvs的整体响应率接近74%.
- 无进展生存时间的中位数为7.5个月 (每周一次) 和11.9个月 (每两周一次).
- 不良事件包括细胞因子释放综合征,皮肤/指甲不良事件,失血症,感染和神经毒性.
结论:
- 塔尔基塔马布-tgvs是R/R MM的第一类抗GPRC5DT细胞重定向双特异抗体.
- 对于严重预治疗的患者来说,它是一个令人信服的选择,尽管需要长期数据和比较研究.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493